Barclays analyst Peter Warendorf initiated coverage of HealthEquity (HQY) with an Overweight rating and $118 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity Inc. Reports Strong Q3 Earnings and Growth
- HealthEquity price target raised to $120 from $117 at Deutsche Bank
- HealthEquity’s Strong Q3 Performance and Raised Guidance Justify Buy Rating with Significant Upside Potential
- Balanced Outlook for Healthequity Amid Strong Performance and Economic Uncertainty Justifies Hold Rating
- HealthEquity price target raised to $129 from $126 at JPMorgan